22nd Century Group Inc
Change company Symbol lookup
Select an option...
XXII 22nd Century Group Inc
ALEC Alector Inc
BABA Alibaba Group Holding Ltd
JEQ abrdn Japan Equity Fund, Inc.
BAC Bank of America Corp
RVLWF Revitalist Lifestyle and Wellness Ltd
$NQUS45101010LMEURN Nasdaq US Brewers Large Mid Cap Net
$R25IG Russell 2500 Growth Index
TTC Toro Co
MPVDF Mountain Province Diamonds Inc
Go

Consumer Staples : Tobacco | Small Cap Growth
Company profile

22nd Century Group, Inc. is an agricultural biotechnology and intellectual property company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new plants with optimized alkaloid and flavonoid profiles, as well as improved yields and valuable agronomic traits. It has developed very low nicotine content (VLNC) tobacco and cigarettes, which contain 95% less nicotine than conventional tobacco and cigarettes. Its reduced nicotine cigarettes include VLN King and VLN Menthol King. In hemp, the Company is developing hemp varieties with increased levels of certain cannabinoids and other desirable agronomic traits. The Company has an interest in RX Pharmatech Ltd (RXP).

Closing Price
$1.06
Day's Change
-0.03 (-2.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.12
Day's Low
1.06
Volume
(Light)
Volume:
871,405

10-day average volume:
1,162,716
871,405

AbbVie Inc. Stock Rises Thursday, Still Underperforms Market

4:32 pm ET November 10, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) rallied 1.42% to $149.72 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 5.54% to 3,956.37 and the Dow Jones Industrial Average rising 3.70% to 33,715.37. AbbVie Inc. closed $26.19 below its 52-week high ($175.91), which the company achieved on April 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Pfizer Inc. (PFE) rose 1.41% to $47.38, Eli Lilly & Co. (LLY) rose 1.50% to $368.72, and AstraZeneca PLC ADR (AZN.LN) rose 6.62% to $65.09. Trading volume (5.6 M) remained 37,597 below its 50-day average volume of 5.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 10, 2022.

	

(END) Dow Jones Newswires

November 10, 2022 16:32 ET (21:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.